Mark Pykett serves as Chief Executive Officer of Myrtelle. He joined the company in 2021 at its inception, bringing over 25 years of pharmaceutical industry executive management experience. Prior to Myrtelle, Mark was Chief Scientific Officer at PTC Therapeutics where he oversaw the company’s discovery, research, and translational activities. Before PTC, he was CEO of Agilis Biotherapeutics (acquired by PTC), CEO of Navidea Pharmaceuticals, President and Chief Operating Officer of Alseres Pharmaceuticals, President of CyGenics and CEO of Cytomatrix (acquired by CyGenics). He is or previously was a board member of both public and private companies, including the biotech companies, and the not-for-profit organization HealthBuilders, developing healthcare infrastructure in Rwanda. Mark holds a BA from Amherst College, a VMD and PhD from the University of Pennsylvania, and an MBA from Northeastern University. He also completed post-doctoral work at the University of Pennsylvania and Harvard University. Mark has dedicated a substantial portion of his career to advancing innovative medicines for rare diseases. He counts among his most rewarding experiences the approval of Evrysdi for spinal-muscular atrophy (SMA), the development of the gene therapy Upstaza for AADC deficiency, the approval and commercial launch of Lymphoseek for cancer, and the scientific innovations Altropane for Parkinson’s disease and the stem cell immunotherapy platform CytoMatrix. Mark is passionate about bringing novel therapies to patients who all too often are overlooked or left behind in the quest for new cures.